Injective Surges 9.73% as Institutional Interest and Bullish Indicators Converge

Injective ($INJ) is currently experiencing a surge of interest from both traders and institutions, driven by strong technical indicators and recent institutional developments. The token is trading at $14.93, reflecting a 9.73% gain over the past 24 hours.

Technical analysis reveals a bullish divergence on both the Relative Strength Index (RSI) and the Moving Average Convergence Divergence (MACD) indicators. The RSI has been forming higher lows since mid-2022, while the price action has continued to form lower lows through early 2025. This divergence suggests that downward pressure is weakening and bullish momentum is building. On the MACD, the line and histogram are curving upwards, forming rising lows and pushing toward a bullish crossover. Historically, such movements across both indicators often precede sharp directional changes in price, signaling a potential trend reversal for $INJ.

Analysts have also noted that $INJ is showing strength following a confirmed Market Structure Shift (MSS). The token has held above the key support range between $14.50 and $14.80, and price is reacting positively after filling a fair value gap (FVG). If $INJ maintains strength above this zone, a continuation toward the $16 mark becomes increasingly probable. However, a healthy retracement into unfilled FVGs below $13 could offer long-term bulls a high-reward entry. These technical setups reflect how smart money often positions ahead of trend continuation.

On the institutional front, Canary Capital has filed with the SEC to launch the first-ever U.S.-staked Injective ETF. This product differs from traditional ETFs by staking the underlying $INJ tokens, allowing investors to earn rewards while contributing to Injective’s network security. The filing positions Injective among a small group of projects with exposure to regulated U.S. financial markets, bridging DeFi and TradFi. This institutional initiative adds weight to the ongoing narrative around Injective’s growing adoption, as developments in traditional finance begin to align with on-chain strength.

With rising volume, technical confirmation, and institutional support converging, Injective appears poised for further momentum in the short to medium term. The combination of bullish technical indicators and institutional developments suggests that $INJ is set for a major move, potentially reversing its multi-month price trend.